Literature DB >> 12782590

Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity.

Asim Saha1, Sunil K Chatterjee, Kenneth A Foon, F James Primus, Malaya Bhattacharya-Chatterjee.   

Abstract

In this study, using the carcinoembryonic antigen (CEA)-expressing C15 murine colon carcinoma system in syngeneic C57BL/6 mice, we have evaluated the efficacy of bone marrow-derived dendritic cells (DCs) pulsed with the murine anti-idiotype antibody 3H1 as a tumor vaccine. Anti-idiotype 3H1 mimics a distinct and specific epitope of CEA and can generate anti-CEA immunity in mice, rabbits, monkeys, and humans when used with a conventional immune adjuvant. Our goal was to determine whether the use of DC as direct antigen-presenting cells would improve the potency of 3H1 as vaccine. Bone marrow-DC pulsed with 3H1 and injected into naïve mice induced both humoral and cellular anti-3H1, as well as anti-CEA immunity. Specific killing of C15 cells in in vitro antibody-dependent cellular cytotoxicity has been observed by immune sera. Immune-splenic lymphocytes when stimulated in vitro with 3H1 or CEA, showed increased proliferative CD4(+) Th1 type T-cell response and secreted significantly high levels of Th1 cytokines [IFN-gamma, interleukin (IL)-2] and low levels of Th2 cytokines (IL-4, IL-10). This vaccine also induced MHC class I antigen-restricted CD8(+) T-cell responses. The up-regulation of activation markers CD69 and CD25 on CD8(+) CTLs correlated with antigen-specific strong CTL responses in vitro. The immunity induced in mice resulted in a complete rejection of CEA-expressing C15 tumor cells in 100% of experimental mice, whereas no protection was observed when 3H1-pulsed DC-vaccinated mice were challenged with CEA-negative MC-38 cells. The tumor rejection in 3H1-pulsed DC-treated mice was associated with the induction of a memory response that helped those mice to survive a second challenge with a lethal dose of C15 cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12782590

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  3 in total

Review 1.  Immunogenic properties of immunoglobulin superfamily members within complex biological networks.

Authors:  Josué Odales; Jesus Guzman Valle; Fernando Martínez-Cortés; Karen Manoutcharian
Journal:  Cell Immunol       Date:  2020-10-11       Impact factor: 4.868

2.  Isolation and characterisation of a human anti-idiotypic scFv used as a surrogate tumour antigen to elicit an anti-HER-2/neu humoral response in mice.

Authors:  M Coelho; P Gauthier; M Pugnière; F Roquet; A Pèlegrin; I Navarro-Teulon
Journal:  Br J Cancer       Date:  2004-05-17       Impact factor: 7.640

3.  A novel cancer immunotherapy based on the combination of a synthetic carbohydrate-pulsed dendritic cell vaccine and glycoengineered cancer cells.

Authors:  Lei Qiu; Jie Li; Shichong Yu; Qianli Wang; Yinghua Li; Zhenlin Hu; Qiuye Wu; Zhongwu Guo; Junping Zhang
Journal:  Oncotarget       Date:  2015-03-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.